metaLead funded by the UZH Life Science Fund
metaLead Therapeutics AG, founded in 2023 as a spin-off of the University of Zurich, announces a CHF 1 Million funding from the UZH Life Sciences Fund. metaLead is developing a new class of metal-binding drugs aimed at overcoming the shortcomings of existing chelation therapies. Its proprietary peptide-based platform offers greater selectivity, targeting toxic metals while preserving essential ones—a key limitation in current treatments.
«The investment from the UZH Life Sciences Fund to advance our treatment for Wilson disease is a significant step forward in our mission to bring better therapies to patients affected by metal-related diseases.» said Michal Shoshan, CEO and founder of metaLead.
Michal Soshan was awarded a UZH Entrepreneur Fellowship in 2023 to accompany and financially support her on her path to becoming an entrepreneur.
New Spin-Offs with Innovative Technology: Spin-offs from UZH are bringing ideas that emerge from research to the market. Six new spin-offs were founded last year. Read the UZH Newsarticle
